A federal judge in Maine issued an order blocking the implementation of the government's 340B drug‑pricing rebate pilot 'pending further order,' court filings show. The decision represents a legal setback for HHS initiatives aimed at altering rebate flows under the 340B program and a victory for drugmakers that challenged the pilot’s legality. The block comes days before the pilot’s planned effective date and adds uncertainty to HHS’ broader policy agenda on drug pricing and rebates. Litigation may delay or reshape future pilot iterations and influence payer‑provider negotiations tied to 340B reimbursement. Pharmaceutical companies that argued the pilot exceeded agency authority welcomed the ruling; health systems and advocacy groups supporting the pilot warned of potential impacts on program integrity and patient access. The case is likely to proceed through additional motions and appeals. Market participants will watch subsequent court orders and any administrative responses from HHS to assess regulatory risk for manufacturers and covered entities.